BioSpace News Archive

Drug Development

Gilead to Test Antiviral Drug Remdesivir in Pediatric Patients with COVID-19

The company announced it planned to soon start enrolling an open-label, single-arm Phase II/III clinical trial of remdesivir in about 50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents.

June 18, 2020
·
3 min read
·
Mark Terry
Drug Development

Roche’s Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study

In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.

June 18, 2020
·
2 min read
·
Alex Keown
Biotech Beach

Engrail Emerges with $32 Million and a Goal of Developing New Neurological Treatments

Vikram Sudarsan, president and chief executive officer of Engrail, said the latest strides made in the field of neuroscience have buoyed the hopes of investors such as NFLS in funding drug development in this area.

June 18, 2020
·
2 min read
·
Alex Keown
Drug Development

Pfizer and Sangamo Release Updated Gene Therapy Data in Hemophilia A

Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.

June 18, 2020
·
3 min read
·
Alex Keown
Drug Development

Recordati Announces Positive Phase III Results for ISTURISA in Cushing’s Patients

Specifically, the product was examined for its use in subjects where pituitary surgery is not an option or has not be curative.

June 18, 2020
·
3 min read
·
Krystle Vermes
Business

Tonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine Collaboration

Plan to Produce Blueprint of How the Human Immune System Responds to Infection Caused by SAR-CoV-2, the Virus that Causes COVID-19

June 18, 2020
·
10 min read
Deals

CryoLife Announces Offering of Convertible Senior Notes Due 2025

CryoLife, Inc. announced that it intends to offer, subject to market conditions and other factors, $100,000,000 aggregate principal amount of convertible senior notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

June 18, 2020
·
4 min read
Business

Bristol Myers Squibb to Announce Results for Second Quarter 2020 on August 6, 2020

Bristol Myers Squibb Company will announce results for the second quarter of 2020 on Thursday, August 6, 2020. During a conference call at 8:30 a.m. ET on August 6, 2020, company executives will review financial results and will address inquiries from investors and analysts.

June 18, 2020
·
1 min read
Genetown

Alnylam to Host Seventh Annual “RNAi Roundtable” Webcast Series

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that it plans to host its 7th annual series of “RNAi Roundtable” webinars over the coming weeks.

June 18, 2020
·
3 min read
Biotech Bay

IncellDx Files Patent for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19 and Other Cytokine Storm Conditions

Company files Pre-EUA with FDA for CCR5 Receptor Occupancy and COVID cytokine panel including IL-6, IL-8,TNF-a, GM-CSF, and CCL5/RANTES

June 18, 2020
·
2 min read